logo
Share SHARE
FONT-SIZE Plus   Neg

BioCryst Reveals Favorable Results From Ulodesine In Phase II Clinical Trials

BioCryst Pharmaceuticals Inc (BCRX) Tuesday released positive results from the extension phase of its randomized Phase 2b trial of ulodesine added to allopurinol in patients with gout, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.

The pharmaceutical company engaged in the design, optimization and development of novel small molecule drugs, revealed that the results of the 52-week, blinded Phase 2b safety extension trial confirm that ulodesine continues to be generally safe and well-tolerated in gout patients who inadequately responded to allopurinol alone, many of which had multiple co-morbidities. No clinical adverse event signals were observed that distinguished ulodesine from placebo, either by type or by rate at the doses tested.

Ulodesine is a novel enzyme inhibitor with the potential for once-a-day oral dosing suitable for chronic administration to treat gout. It acts upstream of xanthine oxidase (XO) in the purine metabolism pathway to reduce new formation of uric acid in patients with gout.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
PepsiCo Inc. (PEP) is bringing back Crystal Pepsi, the colorless soda launched in 1992, a move that the food and beverages giant expects will boost its slowing sales. The 1990s-era clear soda will go on sale in 20-ounce bottles for a limited time at major retailers starting July 7 in Canada and August... The U.S. Federal Communications Commission Wednesday said it has finished the first stage of a spectrum auction and has acquired $86.4 billion worth of wireless airwaves from television broadcasters in a reverse bid. The FCC will now will sell the TV spectrum to cellular service providers in a forward... Allegiant Air will start offering service from Newark Liberty International Airport, after the low-cost airlines received approval from the Federal Aviation Administration. Allegiant will begin offering flights in November between Newark and Cincinnati, Ohio; Savannah, Georgia; Asheville, North Carolina...
comments powered by Disqus
Follow RTT